Repligen Corporation Common Stock vs Thomson Reuters Corp — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Thomson Reuters Corp trades at $106.46 (market cap $45.37B). The key difference: Thomson Reuters Corp is far larger — about 4.1× Repligen Corporation Common Stock's market cap, and Thomson Reuters Corp pays a 2.49% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Thomson Reuters Corp for 63 Days on average.
| RGEN | TRI | |
|---|---|---|
Market Cap | $11.14B | $45.37B |
Volume | 1,259,263 | 729,201 |
Sector | Health | Industrials |
52-Week High | $194.57 | $163.45 |
52-Week Low | $102.87 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $11.02B | $47.98B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Thomson Reuters (TRI) trades at $105.40, up 1.1% today, with a bullish technical outlook and strong analyst support. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while maintaining robust profitability with a 21.22% net income margin. Recent strategic moves include divesting its Global Print business to focus on technology and launching a proprietary AI model, reinforcing its competitive edge in legal and tax solutions.
The stock offers upside to the consensus price target of $128.60, supported by recurring revenue growth and AI expansion, but faces risks from cybersecurity incidents and integration challenges from recent divestitures. Valuation multiples like a P/E of 27.69 suggest premium pricing, requiring sustained execution to justify further gains.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →